GSK plc (LSE/NYSE: GSK) is pleased to announce that at a General Meeting held at 2.30 pm on Wednesday 6 July 2022 both resolutions set out in the Notice of General Meeting (included in the Circular to shareholders published on 1 June 2022) were duly passed by shareholders.

It is therefore expected that the proposed demerger of Haleon plc (‘Haleon’) will be completed and that Haleon shares will be admitted to trading on the London Stock Exchange’s Main Market for listed securities at 8.00 am (UK time) on Monday 18 July 2022. The GSK Share Consolidation is expected to become effective after 8.00 pm (UK time) on Monday 18 July 2022.

Further information on key dates in relation to the proposed demerger of Haleon and the GSK Share Consolidation is set out at the end of this announcement (‘Expected Timetable of Principal Events’) and can also be found in the Circular to Shareholders published on 1 June 2022. The Circular is available on GSK’s website at www.gsk.com/demerger.

The table below provides the results of the poll.

see & read morte on
https://www.gsk.com/en-gb/media/press-releases/result-of-general-meeting/

Shareholders were able to join the General Meeting virtually via Lumi, Zoom and in person. The full text of the two resolutions tabled at the General Meeting is contained in the Notice of General Meeting on pages 157 to 159 of the Circular to Shareholders published on 1 June 2022.

All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.

The above poll results will shortly be available on GSK’s website at www.gsk.com. In accordance with Listing Rule 9.6.2 of the UK Listing Rules, a copy of the resolutions will be submitted to the Financial Conduct Authority and will in due course be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

V A Whyte
Company Secretary
6 July 2022

Notes:

Dr Vishal Sikka’s appointment as a Non-Executive Director will become effective on 18 July 2022. His appointment was announced on 4 May 2022.

The following table provides further relevant information on the General Meeting:
see & read morte on
https://www.gsk.com/en-gb/media/press-releases/result-of-general-meeting/